Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis

European Respiratory Journal

Volumn 48, Issue 4, 2016, Pages 1171-1183

  Fernandez, Isis E ^a   Greiffo, Flavia R ^a   Frankenberger, Marion ^a   Bandres, Julia ^a   Heinzelmann, Katharina ^a   Neurohr, Claus ^a,b   Hatz, Rudolf ^b   Hartl, Dominik ^c,d   Behr, Jürgen ^a,b   Eickelberg, Oliver ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b ASKLEPIOS FACHKLINIKEN MÜNCHEN GAUTING   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD3 ANTIGEN; CD33 ANTIGEN; CD4 ANTIGEN; CD66B ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR7; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; ARTICLE; BIOACCUMULATION; BONE MARROW CELL; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOWN REGULATION; FEMALE; FIBROSING ALVEOLITIS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FORCED VITAL CAPACITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE; LUNG FUNCTION; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; T LYMPHOCYTE; AGED; BLOOD; CASE CONTROL STUDY; CELL SEPARATION; COCULTURE; CYTOLOGY; DISEASE EXACERBATION; IMMUNE SYSTEM; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; LUNG; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; CELL SEPARATION; COCULTURE TECHNIQUES; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; IMMUNE SYSTEM; LEUKOCYTES, MONONUCLEAR; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYELOID-DERIVED SUPPRESSOR CELLS; PROGNOSIS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RNA, MESSENGER;

EID: 84990060974     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01826-2015     Document Type: Article

References (59)

1. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
2. Wuyts WA, Antoniou KM, Borensztajn K, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir Med 2014; 2: 933-942.
3. Zoz DF, Lawson WE, Blackwell TS. Idiopathic pulmonary fibrosis: a disorder of epithelial cell dysfunction. Am J Med Sci 2011; 341: 435-438.
4. Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 2012; 380: 680-688.
5. Reilkoff RA, Peng H, Murray LA, et al. Semaphorin 7a+ regulatory T-cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013; 187: 180-188.
6. Gilani SR, Vuga LJ, Lindell KO, et al. CD28 down-regulation on circulating CD4 T-cells is associated with poor prognoses of patients with idiopathic pulmonary fibrosis. PloS One 2010; 5: e8959.
7. Herazo-Maya JD, Noth I, Duncan SR, et al. Peripheral blood mononuclear cell gene expression profiles predict poor outcome in idiopathic pulmonary fibrosis. Sci Transl Med 2013; 5: 205ra136.
8. Kotsianidis I, Nakou E, Bouchliou I, et al. Global impairment of CD4+CD25+FOXP3+ regulatory T-cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 1121-1130.
9. Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011; 208: 1339-1350.
10. Moore BB, Fry C, Zhou Y, et al. Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. Front Med 2014; 1: pii00056.
11. Lindau D, Gielen P, Kroesen M, et al. The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T-cells and natural killer T-cells. Immunology 2013; 138: 105-115.
12. Talmadge JE, Gabrilovich DI. History of myeloid-derived suppressor cells. Nat Rev Cancer 2013; 13: 739-752.
13. Damuzzo V, Pinton L, Desantis G, et al. Complexity and challenges in defining myeloid-derived suppressor cells. Cytom Part B Clin Cytom 2015; 88: 77-91.
14. Lees JR, Azimzadeh AM, Bromberg JS. Myeloid derived suppressor cells in transplantation. Curr Opin Immunol 2011; 23: 692-697.
15. Vollbrecht T, Stirner R, Tufman A, et al. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 2012; 26: F31-F37.
16. Li Y, Tu Z, Qian S, et al. Myeloid-derived suppressor cells as a potential therapy for experimental autoimmune myasthenia gravis. J Immunol 2014; 193: 2127-2134.
17. Feng PH, Lee KY, Chang YL, et al. CD14+S100A9+ monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer. Am J Respir Crit Care Med 2012; 186: 1025-1036.
18. du Plessis N, Loebenberg L, Kriel M, et al. Increased frequency of myeloid-derived suppressor cells during active tuberculosis and after recent Mycobacterium tuberculosis infection suppresses T-cell function. Am J Respir Crit Care Med 2013; 188: 724-732.
19. Rieber N, Brand A, Hector A, et al. Flagellin induces myeloid-derived suppressor cells: implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol 2013; 190: 1276-1284.
20. Kalathil SG, Lugade AA, Pradhan V, et al. T-regulatory cells and programmed death 1+ T-cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 190: 40-50.
21. Kolahian S, Öz HH, Zhou B, et al. The emerging role of myeloid-derived suppressor cells in lung diseases. Eur Respir J 2016; 47: 967-977.
22. Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. an update of the 2011 Clinical Practice Guideline Am J Respir Crit Care Med 2015; 192: e3-e19.
23. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human Immunology Project. Nat Rev Immunol 2012; 12: 191-200.
24. Heimbeck I, Hofer TP, Eder C, et al. Standardized single-platform assay for human monocyte subpopulations: lower CD14+CD16++ monocytes in females. Cytom Part A 2010; 77: 823-830.
25. Kostlin N, Kugel H, Spring B, et al. Granulocytic myeloid derived suppressor cells expand in human pregnancy and modulate T-cell responses. Eur J Immunol 2014; 44: 2582-2591.
26. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest 2015; 125: 3356-3364.
27. Franklin RA, Liao W, Sarkar A, et al. The cellular and molecular origin of tumor-associated macrophages. Science 2014; 344: 921-925.
28. Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968-1977.
29. Lo Re S, Lison D, Huaux F. CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions. J Leukoc Biol 2013; 93: 499-510.
30. Marchal-Somme J, Uzunhan Y, Marchand-Adam S, et al. Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis. J Immunol 2006; 176: 5735-5739.
31. Mack DG, Lanham AM, Palmer BE, et al. CD27 expression on CD4+ T-cells differentiates effector from regulatory T-cell subsets in the lung. J Immunol 2009; 182: 7317-7324.
32. Liu F, Liu J, Weng D, et al. CD4+CD25+Foxp3+ regulatory T-cells depletion may attenuate the development of silica-induced lung fibrosis in mice. PLoS One 2010; 5: e15404.
33. Yang IV, Luna LG, Cotter J, et al. The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One 2012; 7: e37708.
34. Srivastava MK, Bosch JJ, Thompson JA, et al. Lung cancer patients' CD4+ T-cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008; 57: 1493-1504.
35. Zhang Y, Liu Q, Zhang M, et al. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801-3808.
36. Knaul JK, Jorg S, Oberbeck-Mueller D, et al. Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis. Am J Respir Crit Care Med 2014; 190: 1053-1066.
37. Yeager ME, Nguyen CM, Belchenko DD, et al. Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension. Chest 2012; 141: 944-952.
38. Peyvandi S, Buart S, Samah B, et al. Fas ligand deficiency impairs tumor immunity by promoting an accumulation of monocytic myeloid-derived suppressor cells. Cancer Res 2015; 75: 4292-4301.
39. Verschoor CP, Johnstone J, Millar J, et al. Blood CD33+HLA-DR- myeloid-derived suppressor cells are increased with age and a history of cancer. J Leukoc Biol 2013; 93: 633-637.
40. Fernandez IE, Eickelberg O. The impact of TGF-β on lung fibrosis: from targeting to biomarkers. Proc Am Thorac Soc 2012; 9: 111-116.
41. Corzo CA, Condamine T, Lu L, et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010; 207: 2439-2453.
42. Zhong H, Gutkin DW, Han B, et al. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer 2014; 134: 2633-2645.
43. Shi Y, Ou L, Han S, et al. Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes. Oncogenesis 2014; 3: e129.
44. Niedermeier M, Reich B, Rodriguez Gomez M, et al. CD4+ T-cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc Natl Acad Sci USA 2009; 106: 17892-17897.
45. Zhang H, Maric I, DiPrima MJ, et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer. Blood 2013; 122: 1105-1113.
46. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
47. Garcia de Alba C, Buendia-Roldan I, Salgado A, et al. Fibrocytes contribute to inflammation and fibrosis in chronic hypersensitivity pneumonitis through paracrine effects. Am J Respir Crit Care Med 2015; 191: 427-436.
48. Walter S, Weinschenk T, Stenzl A, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18: 1254-1261.
49. Wang Z, Zhang Y, Liu Y, et al. Association of myeloid-derived suppressor cells and efficacy of cytokine-induced killer cell immunotherapy in metastatic renal cell carcinoma patients. J Immunother 2014; 37: 43-50.
50. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. Hematol Oncol 2013; 31: 65-71.
51. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T-cells and NY-ESO-1- or melan-A-specific T-cells. Clin Cancer Res 2014; 20: 1601-1609.
52. Vasquez-Dunddel D, Pan F, Zeng Q, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013; 123: 1580-1589.
53. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-1560.
54. Wang L, Chang EW, Wong SC, et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J Immunol 2013; 190: 794-804.
55. Yu J, Du W, Yan F, et al. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol 2013; 190: 3783-3797.
56. Schilling B, Sucker A, Griewank K, et al. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells. Int J Cancer 2013; 133: 1653-1663.
57. Verma C, Eremin JM, Robins A, et al. Abnormal T-regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T-helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC. J Transl Med 2013; 11: 16.
58. Iclozan C, Antonia S, Chiappori A, et al. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62: 909-918.
59. Mirza N, Fishman M, Fricke I, et al. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res 2006; 66: 9299-9307.